Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite™ Sensor, the ...

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) announces the launch of Enlite™ Sensor, the newest and most advanced glucose sensor for continuous glucose monitoring (CGM), in more than 35 ...

The FDA has approved the Enlite sensor for use with Medtronic’s iPro2 Professional Continuous Glucose Monitoring system, a disposable glucose sensor that can be worn for up to 6 days. The Enlite ...

Medtronic plc (NYSE: MDT) disclosed that the FDA has given its approval of the Enlite sensor for use with iPro2 Professional Continuous Glucose Monitoring (CGM) system. This is a market-leading CGM ...

MINNEAPOLIS - September 27, 2013 -Medtronic, Inc. (MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the MiniMed ® 530G with Enlite ®, a breakthrough, first-generation ...

Medtronic plc (NYSE:MDT) recently announced the receipt of the U.S. FDA approval for its Enlite sensor, which is to be used with the iPro2 Professional Continuous Glucose Monitoring (CGM) system. This ...

With a great deal of hype, and a few delays from the US Food and Drug Administration (FDA), Medtronic in September 2013 released its newest combined pump and continuous glucose monitor (CGM), the ...

iPro2 Professional CGM with Enlite Provides Critical Link Between Glucose Variability and Lifestyle for Improved Diabetes Control DUBLIN - Sept. 1, 2016 - Medtronic plc (MDT), the global leader in ...